Elias Karam, Hematology-Medical Oncology Fellow at Gustave Roussy, shared a post on LinkedIn:
“Endocrine resistance is being redefined after SERENA-6 !! Slide by Shaheena Daoud at the MEA Breast Cancer Summit in Dubai by AstraZeneca.
In HR+ breast cancer, resistance is no longer just about radiologic progression.
Molecular progression can appear earlier, and recognizing it allows timely intervention, delayed chemotherapy, and longer PFS.
We’re shifting from reacting to imaging to anticipating molecular change…a step closer to true precision oncology.”
More posts featuring Elias Karam on OncoDaily.